دورية أكاديمية
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma
| العنوان: | Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma |
|---|---|
| المؤلفون: | Carroll, Thomas M., Chadwick, Joseph A., Owen, Richard P., White, Michael J., Kaplinsky, Joseph, Peneva, Iliana, Frangou, Anna, Xie, Phil F., Chang, Jaeho, Roth, Andrew, Amess, Bob, James, Sabrina A., Rei, Margarida, Fuchs, Hannah S., McCann, Katy J., Omiyale, Ayo O., Jacobs, Brittany-Amber, Lord, Simon R., Norris-Bulpitt, Stewart, Dobbie, Sam T., Griffiths, Lucinda, Ramirez, Kristen Aufiero, Ricciardi, Toni, Macri, Mary J., Ryan, Aileen, Venhaus, Ralph R., Van den Eynde, Benoit, Karydis, Ioannis, Schuster-Böckler, Benjamin, Middleton, Mark R., Lu, Xin |
| المساهمون: | UCL - SSS/DDUV/GECE - Génétique cellulaire |
| المصدر: | Cancer Cell, Vol. 41, no.7, p. 1222-1241.e7 (2023) |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2023 |
| المجموعة: | DIAL@USL-B (Université Saint-Louis, Bruxelles) |
| مصطلحات موضوعية: | Cancer Research, Oncology |
| الوصف: | For inoperable esophageal adenocarcinoma (EAC), identifying patients likely to benefit from recently approved immunochemotherapy (ICI+CTX) treatments remains a key challenge. We address this using a uniquely designed window-of-opportunity trial (LUD2015-005), in which 35 inoperable EAC patients received first-line immune checkpoint inhibitors for four weeks (ICI-4W), followed by ICI+CTX. Comprehensive biomarker profiling, including generation of a 65,000-cell single-cell RNA-sequencing atlas of esophageal cancer, as well as multi-timepoint transcriptomic profiling of EAC during ICI-4W, reveals a novel T cell inflammation signature (INCITE) whose upregulation correlates with ICI-induced tumor shrinkage. Deconvolution of pre-treatment gastro-esophageal cancer transcriptomes using our single-cell atlas identifies high tumor monocyte content (TMC) as an unexpected ICI+CTX-specific predictor of greater overall survival (OS) in LUD2015-005 patients and of ICI response in prevalent gastric cancer subtypes from independent cohorts. Tumor mutational burden is an additional independent and additive predictor of LUD2015-005 OS. TMC can improve patient selection for emerging ICI+CTX therapies in gastro-esophageal cancer. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1535-6108 |
| العلاقة: | boreal:278087; http://hdl.handle.net/2078.1/278087Test; urn:ISSN:1535-6108 |
| DOI: | 10.1016/j.ccell.2023.06.006 |
| الإتاحة: | https://doi.org/10.1016/j.ccell.2023.06.006Test http://hdl.handle.net/2078.1/278087Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.6E15814A |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 15356108 |
|---|---|
| DOI: | 10.1016/j.ccell.2023.06.006 |